Last reviewed · How we verify
NCT03575390
The Beneficial Effects of Pomegranate on Hearing of Patients Without Hemodialysis
NA trial testing Placebo in Hearing Impairment in 120 participants. Completed in 31 January 2022.
31 January 2022
Quick facts
| Lead sponsor | Dalin Tzu Chi General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 120 |
| Start date | 30 March 2018 |
| Primary completion | 31 January 2022 |
| Estimated completion | 31 January 2022 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Placebo
- Pomegranate
Conditions studied
- Hearing Impairment — all drugs for Hearing Impairment →
Sponsor
Dalin Tzu Chi General Hospital
Who can join
Adults 50 to 80, any sex, with Hearing Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pomegranate has anti-oxidative capacity. It might reduce symptoms of Alzheimer's disease, Drug-induced hepatitis, and might prevent deterioration of cardiovascular diseases and cancer progression. But, the beneficial effects of pomegranate on hearing impairment was still unclear. This study aimed to investigate the beneficial effects of pomegranate on hearing impairment by a prospective, randomized, double-blinded clinical trial design. The investigators'll include 120 elderly patients without hemodialysis in our hospital, and divided them into 2 groups. Control group will receive placebo treatment; pomegranate group will receive oral pomegranate (500 mg, twice per day). All patients received the above treatment for 9 months, and underwent pure tone audiometry and word discrimination scores before the start of the clinical trial and at the end of the treatment (9th month).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03575390
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hearing Impairment
Currently open trials in the same condition.
- NCT06663917 — Clinical Evaluation of Frequency Allocation for Bimodal CI Users · NA · recruiting
- NCT06680934 — CABP2 Patient Registry and Natural History Study · recruiting
- NCT05847426 — Improving Early Intervention in Hearing Impaired Children Using Functional Near-Infrared Spectroscopy (fNIRS) · NA · recruiting
- NCT05805384 — Evaluating a Noise Reduction Algorithm With Cochlear Implant Users · NA · recruiting
- NCT05946057 — Otoferlin Patient Registry and Natural History Study · recruiting
Other Dalin Tzu Chi General Hospital trials
Trials by the same sponsor.
- NCT07180485 — Effectiveness of Whole Body Vibration on Health Outcomes in Older Adults With Dynapenic Abdominal Obesity · NA · not yet recruiting
- NCT06963125 — The Effects of Prune Juice on Bowel Movement Patterns, Constipation Symptoms, and Quality of Life · NA · recruiting
- NCT06791980 — Integrated Care Approach for Rheumatoid Arthritis Patients · NA · completed
- NCT06344169 — Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section · Phase 2, PHASE3 · recruiting
- NCT06875115 — Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03575390 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dalin Tzu Chi General Hospital
- Last refreshed: 5 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03575390.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing